<code id='CC919D9115'></code><style id='CC919D9115'></style>
    • <acronym id='CC919D9115'></acronym>
      <center id='CC919D9115'><center id='CC919D9115'><tfoot id='CC919D9115'></tfoot></center><abbr id='CC919D9115'><dir id='CC919D9115'><tfoot id='CC919D9115'></tfoot><noframes id='CC919D9115'>

    • <optgroup id='CC919D9115'><strike id='CC919D9115'><sup id='CC919D9115'></sup></strike><code id='CC919D9115'></code></optgroup>
        1. <b id='CC919D9115'><label id='CC919D9115'><select id='CC919D9115'><dt id='CC919D9115'><span id='CC919D9115'></span></dt></select></label></b><u id='CC919D9115'></u>
          <i id='CC919D9115'><strike id='CC919D9115'><tt id='CC919D9115'><pre id='CC919D9115'></pre></tt></strike></i>

          focus

          focus

          author:fashion    Page View:24723
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves
          At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

          BristolCEOChristopherBoernerBusinessWireviaAPSANFRANCISCO— ChristopherBoernerhasbeentheCEOofBristolM

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          JPM: CVS says Medicare Advantage patients are impacting profits

          WilfredoLee/APMedicareAdvantagememberscontinuetogotothedoctorandgethealthcareproceduresalotmorethanp